Monica Barbolini
Overview
Explore the profile of Monica Barbolini including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
246
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Belluzzi L, Martinelli G, Medici B, Farina A, Martinelli E, Canino F, et al.
Breast Cancer (Dove Med Press)
. 2025 Jan;
17:53-66.
PMID: 39867812
In recent years, new anticancer drugs have been investigated and approved for the treatment of breast cancer based on improved survival outcomes. However, these new treatments have specific class-related side...
2.
Canino F, Barbolini M, De Giorgi U, Fontana T, Gaspari V, Gianni C, et al.
BMC Cancer
. 2024 Jun;
24(1):735.
PMID: 38879498
Background: The addition of pertuzumab (P) to trastuzumab (H) and standard chemotherapy (CT) as neoadjuvant treatment (NaT) for patients with HER2 + breast cancer (BC), has shown to increase the...
3.
Canino F, Tornincasa A, Bettelli S, Manfredini S, Barbolini M, Moscetti L, et al.
Int J Mol Sci
. 2024 Mar;
25(5).
PMID: 38473737
Over the last two decades, the use of Next-Generation Sequencing (NGS) in medical oncology has increased the likelihood of identifying druggable mutations that may be potentially susceptible to targeted treatments....
4.
DOnofrio R, Sperduti I, Piacentini F, Barbolini M, Omarini C, Toss A, et al.
Clin Breast Cancer
. 2023 Sep;
23(8):e534-e541.
PMID: 37775349
The adjuvant endocrine therapy (AET) of HR+ EBC has been changing in recent years. Aromatase inhibitors (AIs) as an upfront strategy (or as part of a switch strategy) have been...
5.
DOnofrio R, Omarini C, Toss A, Sperduti I, Piacentini F, Barbolini M, et al.
Clin Breast Cancer
. 2023 Jul;
23(7):712-720.e3.
PMID: 37507257
Background: Ovarian function suppression (OFS) and hormone therapy (HT) represent an adjuvant option in premenopausal hormone receptor-positive early breast cancer (HR+EBC). The SOFT-TEXT trials showed improved outcomes upon receiving aromatase...
6.
Cerma K, Piacentini F, Moscetti L, Barbolini M, Canino F, Tornincasa A, et al.
Biomedicines
. 2023 Jan;
11(1).
PMID: 36672617
Breast cancer (BC) is the most common women cancer and cause of cancer death. Despite decades of scientific progress in BC treatments, the clinical benefit of new drugs is modest...
7.
Toss A, Venturelli M, Civallero M, Piombino C, Domati F, Ficarra G, et al.
Front Oncol
. 2022 Dec;
12:1016295.
PMID: 36531080
Introduction: Triple-negative breast cancer (TNBC) patients who do not obtain pathological complete response (pCR) after neoadjuvant chemotherapy (NACT) present higher rate of relapse and worse overall survival. Risk factors for...
8.
Canino F, Piacentini F, Omarini C, Toss A, Barbolini M, Vici P, et al.
Int J Mol Sci
. 2022 Jul;
23(13).
PMID: 35806079
Endocrine therapy (ET), associated with CDK 4/6 inhibitors, represents the first choice of treatment for HR+/HER2- metastatic breast cancer (mBC). Primary or secondary endocrine resistance could develop; however validated biomarkers...
9.
Omarini C, Piacentini F, Sperduti I, Cerma K, Barbolini M, Canino F, et al.
BMC Cancer
. 2022 Jun;
22(1):623.
PMID: 35672679
Background: Current guidelines consider T-DM1 the standard 2 line therapy for HER2 positive metastatic breast cancer (MBC) patients following trastuzumab (T) + pertuzumab (P) and taxane 1 line treatment. Despite...
10.
Isca C, Piacentini F, Mastrolia I, Masciale V, Caggia F, Toss A, et al.
Cancers (Basel)
. 2021 Oct;
13(19).
PMID: 34638377
MicroRNAs (miRNA) are small noncoding RNAs that can act as both oncogene and tumor suppressors. Deregulated miRNA expression has been detected in human cancers, including breast cancer (BC). Considering their...